key: cord-0751308-7v81l7yd
authors: Jumroendararasame, Chaisiri; Panyakorn, Somboon; Othong, Rittirak; Jumroendararasame, Auraya; Srimanan, Worapot; Tipparut, Kun
title: Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report
date: 2021-09-23
journal: Am J Ophthalmol Case Rep
DOI: 10.1016/j.ajoc.2021.101212
sha: 3d7d13d1e05d791e5e36e5c4c86391d312cd0e95
doc_id: 751308
cord_uid: 7v81l7yd

PURPOSE: The first reported case of bilateral transient visual field defect, experienced by an ophthalmologist, which developed shortly after COVID-19 vaccination (CoronaVac, Sinovac Biotech Ltd., Beijing, China) and confirmed by computerized automated perimetry. OBSERVATION: The patient is a 42-year-old Thai ophthalmologist. He developed blurred vision within an hour after the second dose of COVID-19 vaccination. We described his self-observed of sequential symptoms, chronologic events, and management steps. The visual field of left congruous hemianopia with respect to vertical midline was detected with computerized automated perimetry. The possible mechanism could be related to an acute vasospasm of the artery in the postchiasmatic visual pathway, triggered by COVID-19 vaccine, Corona Vac. CONCLUSION AND IMPORTANCE: With increasing use of the COVID-19 vaccine in the near future, it would be prudent for medical staff and ophthalmologists to be considered and aware of this associated condition.

Since the global spreading of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in December 2019, the situation has worsened, resulted in the pandemic declaration by the World Health Organization (WHO) on March 11 st , 2020. 1 The expedited development and approval of Covid-19 vaccine is an inevitable solution. Many possible side effects of the Covid-19 vaccine have been reported including fever, pain, weakness and paralysis. 2 Vision related adverse effects can be found and had been reported after other vaccination such as influenza 3 , measles, rubella 4 , rabies 5 , tuberculosis 6 , hepatitis B 7 , meningitis 8 , anthrax 9 and tetanus 10 vaccine. However, to the best of our knowledge, there was no report of visual field defect, developed shortly after COVID-19 vaccination (CoronaVac, Sinovac Biotech Ltd., Beijing, China) which was occurred and had been self-detected by an ophthalmologist (CJ).

A 42-year-old Thai male ophthalmologist (CJ), otherwise healthy with a history of good controlled dyslipidemia for 10 years, using Rosuvastatin 20 mg. daily. He received the first dose of Corona Vac (Sinovac Biotech Ltd., lot number A2021010041) on March 24 th , 2021 without serious adverse reactions, only mild muscle sore of the injection site at left deltoid muscle. The second dose of Coronac Vac (lot number J202103002) was injected on April 21, 2021. He developed blurred vision within an hour after vaccination. Sequential symptoms, chronologic events, and management steps were described as followed. At 12.50 pm., the patient had vaccination, and was closely observed in a designated area of the hospital for 30 minutes without any adverse events. Ten minutes later he noticed having a blurred vision starting at the center of his visual field, foggy in character. Scotoma enlarged within a couple of minutes before it obscured the left side of his visual field. He reported as looking through the watery scene but it was not dark. There was no associated headache or any weakness. The patient went back to the ophthalmology department 10 minutes after he had the abnormal vision seeking for an urgent care. The eye examination revealed visual acuity of 20/20 in both eyes, with unremarkable anterior segment, and normal fundus. Neither intra-ocular inflammation nor relative afferent pupillary defect (RAPD) was detected. Optical coherent tomography (OCT) of the macula was normal. He also undergone visual field test with computerized automated perimetry (CTVF, Humphrey HFA II-I 750i field analyzer, Carl Zeiss Meditec, INC, Dublin, CA, USA) program 24-2 fast and the results were as shown in the figure 1.

Stroke fast track then was initiated at 50 minutes after having the blurred vision. Neurological examination was done by neurologists which was unremarkable. At the time, the only remarkable physical examination was his blood pressure (BP) which was found to be mildly elevated at 150/90 mmHg. (his baseline BP: 120/80 mmHg.). Regardless of normal neurological examination, MRI of brain was initiated 20 minutes later, result as in figure 3 . In the meantime, the patient started to have a better vision but still not normal. After the completion of the MRI (2 hours after having the event), the patient reported normalization of his vision and visual field. CTVF was repeated about 2 hours 35 minutes post event, and it became normal, results as shown in figure 2. The patient was admitted to the hospital for intravenous fluid and oral aspirin (325mg.). Extensive investigations had been performed including normal CBC, FBS 86 mg/dL, HbA1C 5.6%, normal BUN/Cr, eGFR 103.58 mL/min/1. No other sequels were detected during the hospital stay, and no recurrence of symptoms, and other abnormalities during two months after the second dose of the CoronaVac injection.

After a vast number of the COVID-19 vaccines were distributed worldwide, we continue to see many emerging reports regarding the adverse drug reactions of these vaccines including pain at the injection site, swelling, fever, headache, fatigue, chills, muscle pain, nausea, diarrhea, rashes and swollen lymph nodes. The chance of any of these adverse effects were different and depend on a specific COVID-19 vaccine. Most of the effects were mild and temporary, however more serious adverse events have been increasingly reported such as the six cases of serious cerebral venous sinus thrombosis after receiving the Johnson & Johnson vaccine which causing the pause of their uses on April 13, 2021 by the CDC. 11 To date and the best of our knowledge, this is the first case report of transient visual field defect after the COVID-19 vaccination (CoronaVac), self-observed by an ophthalmologist and confirmed by the computerized automated perimetry. Many possible mechanisms could explain the cause of this transient bilateral hemianopic visual field defect. The most likely mechanism that we postulated would be related to an acute vasospasm of the artery in the postchiasmatic visual pathway, triggered by COVID-19 immunization. Right occipital lobe is the most likely affected area, characterized by congruous visual field defect with macular sparing 12 , and no other neurological abnormalities. The possible affected vessels would be small branches of middle 13 or posterior 14 cerebral arteries. The normal results on the brain MRI in our case, help excluding other structural abnormalities. Complete recovery of the visual function and visual field at roughly 1-2 hours in our case, suggested the reperfusion of affected arterial system. The differential diagnosis may include the reversible cerebral vasoconstriction syndrome (RCVS) 15 , cerebral venous sinus thrombosis (CVST) 16 , retinal migraine 17 , optic neuritis 18 , multiple evanescent white dot syndrome (MEWDS) 19 , and acute idiopathic blind spot enlargement syndrome (AIBSES) 20 , which would be different in many aspects as the following.

RCVS is a rare condition of sudden constriction of cerebral vasculatures and generally not associated with viral infection but was recently reported to be associated with COVID-19 infection. 19 It is usually associated with an excruciating headache which tends to occur and reaches its peak intensity within seconds. The absence of headache is a rare exception 15, 21 . The brain MRI would have revealed abnormalities such as vasogenic edema, sulcal hyperintensity, intraparenchymal hemorrhage or infarction 22 . The resolution of RCVS components usually takes days to weeks 15 . Absence of severe headache, normal brain MRI, and rapid recovery of our case may not fit with this condition. Migraine is a common J o u r n a l P r e -p r o o f disabling brain disorder. Headache is a key marker and usually occurs during the course of visual disturbance 17 . Repeated episode is needed before making diagnosis of this condition. Solitary visual disturbance in our case would be classified as retinal migraine which usually has an attack only on one eye, or typical migraine with aura but single episode of this bilateral visual field defects without headache makes this condition less likely. CVST is the condition with presence of blood clot in cerebral vein or dural venous sinuses. Symptoms include severe headache, visual disturbance or visual field defect or weakness 16 . The diagnosis can be made by computered tomography (CT) or MRI to demonstrate an obstruction of the venous sinus which is absent in our case. Optic neuritis has been reported to be associated with vaccination, most cases are bilateral which may involve the anterior segment or retrobulbar area 18, 23 . It usually develops within a week to a month after vaccination but could be earlier as in the first 24 hours 3-8,10 , but the findings of visual field test did not fit with our case. MEWDS has been reported following influenza vaccination 24 . Patients usually have symptoms of unilateral blurred vision, photopsia, scotomas and purple hue of the vision. Spontaneous recovery would occur in a range of several weeks 19 . By its characteristics, fundus findings, and laterality do not fit with our patient. AIBSES is a rare condition, and currently believed to be in a spectrum of primary inflammatory choriocapillaropathy (PICCP) 25 . This condition has been reported following influenza vaccination. The patient could present with acute monocular scotoma, with otherwise normal fundus 20 . OCT may show a loss or irregularity of the ellipsoid layer in corresponding area of visual field defect 26 . An enlarged blind spot can only be the sole detected finding, which may resemble to temporal field defect, and mis-interpret if not respect to the midline but our patient had bilateral left hemianopic field with normal macular scan.

By conclusion, we report the first case of transient bilateral visual field defect characteristic of posterior visual pathway, triggered by COVID-19 vaccination. We postulate the possible mechanism would be from acute arterial vasospasm of corresponding branches of middle or posterior cerebral arteries. With increasing use of the COVID-19 vaccine in the near future, it would be prudent for medical staff and ophthalmologists to consider, and be aware of this associated condition J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f All authors attest that they met the current ICMJE criteria.

The following authors have no financial disclosures: (CJ, SP, RO, AJ, WS, KT)

WHO remarks at the media briefing on COVID-19 -11

COVID-19 Vaccine: Critical Questions with Complicated Answers

Optic Neuritis After Influenza Vaccination

Optic Neuritis Complicating Measles, Mumps, and Rubella Vaccination

Bilateral optic neuritis complicating rabies vaccination

Bilateral panuveitis and optic neuritis following Bacillus Calmette-Guérin (BCG) vaccination. Acta Paediatr Oslo Nor

Bilateral retrobulbar optic neuritis with hepatitis B vaccination

Optic neuritis after meningococcal vaccination

Optic neuritis and myelitis after booster tetanus toxoid vaccination

Coronavirus Disease

Late emergence of macular sparing in a stroke patient

Middle Cerebral Artery Stroke

Posterior Cerebral Artery Stroke

Reversible cerebral vasoconstriction syndrome

Cerebral venous sinus thrombosis

Retinal, ophthalmic, or ocular migraine

Optic neuritis

Multiple Evanescent White Dot Syndrome

Acute Idiopathic Blind Spot Enlargement Syndrome: A Review of 27 New Cases

Vascular wall imaging in reversible cerebral vasoconstriction syndrome -a 3-T contrast-enhanced MRI study

Infectious optic neuropathies: a clinical update

Multiple evanescent white dot syndrome following influenza immunization -A multimodal imaging study

Acute idiopathic blind spot enlargement syndrome following influenza vaccination

High-definition optical coherence tomography findings in acute idiopathic blind spot enlargement (AIBSE) syndrome

Dr. Chaisiri Jumroendararasame had full access to all the data in this study and take responsibility for the integrity and the accuracy of the data

The nature of potential conflict of interest is described below:

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no financial support for this work that could have influenced its outcome.

All of the sources of funding for the work described in this publication are acknowledged below:( ) No funding was received for this work. 3. Intellectual Property ( ) We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.( ) Written consent to publish potentially identifying information, such as details or the case and photographs, was obtained from the patient(s) or their legal guardian(s).

The International Committee of Medical Journal Editors (ICMJE) recommends that authorship be based on the following four criteria: 1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND 2. Drafting the work or revising it critically for important intellectual content; AND 3. Final approval of the version to be published; AND J o u r n a l P r e -p r o o f 4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. For more information on authorship, please see http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-therole-of-authors-and-contributors.html#two. We attest that all authors contributed significantly to the creation of this manuscript, each having fulfilled criteria as established by the ICMJE.

We confirm that the manuscript has been read and approved by all named authors.( ) We confirm that the order of authors listed in the manuscript has been approved by all named authors.

The Corresponding Author declared on the title page of the manuscript is:

This author submitted this manuscript using his/her account in EVISE.We understand that this Corresponding Author is the sole contact for the Editorial process (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.We confirm that the email address shown below is accessible by the Corresponding Author, is the address to which Corresponding Author's EVISE account is linked, and has been configured to accept email from the editorial office of American Journal of Ophthalmology Case Reports: